Drug profile · INN
sutimlimab-jome
ENJAYMO
sutimlimab-jome (ENJAYMO) is a complement c1s inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — sutimlimab-jome
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
sutimlimab-jome (ENJAYMO) is a complement c1s inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Complement C1s inhibitor
Primary target: Complement C1s subcomponent
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is sutimlimab-jome?
sutimlimab-jome (ENJAYMO) is a complement c1s inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for sutimlimab-jome?
ENJAYMO is a marketed brand name for sutimlimab-jome. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sutimlimab-jome?
sutimlimab-jome has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.